Skip to main content
. 2022 Aug 3;140(17):1845–1857. doi: 10.1182/blood.2021014586

Table 1.

Patient demographic and disease characteristics

Parameter GIL + AZA (n = 74) AZA (n = 49)
Sex, n (%)
 Male 42 (56.8) 28 (57.1)
 Female 32 (43.2) 21 (42.9)
Race, n (%)
 White 46 (62.2) 29 (59.2)
 Asian 20 (27.0) 13 (26.5)
Age, y
 Mean ± standard deviation 77.4 ± 5.6 76.7 ± 5.3
 Median (minimum, maximum) 78.0 (59, 90) 76.0 (61, 88)
Age group, n (%)
 <75 y 21 (28.4) 13 (26.5)
 ≥75 y 53 (71.6) 36 (73.5)
Body surface area, m2
 n 73 47
 Mean ± standard deviation 1.75 ± 0.22 1.75 ± 0.25
 Median (minimum, maximum) 1.72 (1.4, 2.7) 1.72 (1.2, 2.5)
Baseline ECOG PS, n (%)
 0-1 38 (51.4) 32 (65.3)
 ≥2 35 (47.3) 16 (32.7)
 Missing 1 (1.4) 1 (2.0)
Baseline FLT3 mutation type, n (%)
 ITD alone 58 (78.4) 40 (81.6)
 TKD (D835/I836) alone 14 (18.9) 7 (14.3)
 ITD with TKD (D835/I836) 2 (2.7) 2 (4.1)
Baseline FLT3 mutation status, n (%)
 ITD allelic ratio < 0.5 25 (33.8) 18 (36.7)
 ITD allelic ratio ≥ 0.5 35 (47.3) 24 (49.0)
 TKD 14 (18.9) 7 (14.3)
Cytogenetic risk status, n (%),
 Favorable 2 (2.7) 0
 Intermediate 51 (68.9) 36 (73.5)
 Unfavorable 8 (10.8) 5 (10.2)
 Others (unknown, missing) 13 (17.6) 8 (16.3)

Unknown category includes missing and data not allowed to be collected.

Stratification factors for analysis.

Patients may have reported more than one cytogenetic risk status.